AlphaQuest’s Axsome Therapeutics AXSM Stock Holding History

AlphaQuest’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,408	Closed	-$257K	–	215
2025 Q4	$257K	Buy	1,408 +854	+154%	+$119K	0.01%	1314
2025 Q3	$67.3K	Sell	554 -1,054	-66%	-$119K	﹤0.01%	1855
2025 Q2	$168K	Buy	1,608 +1,280	+390%	+$136K	0.02%	1227
2025 Q1	$38.3K	Buy	+328	New	+$37.4K	﹤0.01%	1583
2024 Q4	–	Sell	-82	Closed	-$7.37K	–	1711
2024 Q3	$7.37K	Buy	+82	New	+$7.16K	﹤0.01%	1565

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlphaQuest's AXSM Position: Q1 2026 in Review

AlphaQuest sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 1,408 shares — an estimated $257K sold.

AlphaQuest first reported a position in AXSM in Q3 2024 and held it in 5 quarters. The position peaked at $257K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

AlphaQuest reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 1,408 Axsome Therapeutics shares in Q1 2026, an estimated $257K.
AlphaQuest first reported a position in Axsome Therapeutics in Q3 2024 and held it in 5 quarters.
AlphaQuest's Axsome Therapeutics position peaked at $257K in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.